Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Honestly I felt the PR this morning was a recipe to drowned for a while and today's opening is a reflection of that.
"India's Biocon secures approval to use drug on coronavirus patients"
https://www.msn.com/en-us/news/world/indias-biocon-secures-approval-to-use-drug-on-coronavirus-patients/ar-BB16C5QY?li=BBnb7Kz
“Israelis angry at Netanyahu over new outbreak, economic pain”
https://www.msn.com/en-us/news/world/israelis-angry-at-netanyahu-over-new-outbreak-economic-pain/ar-BB16zhKA?li=BBnb7Kz
Leo needs to contact Netanyahu ASAP and get him to authorize a quick testing of Brilacidin within the State of Israel in order to help the sick and needy and possibly hang-on to his shoddy political career!
Right back down to yesterday's close... Shysters'!
Head Fake?
Glad to see the spread tighten up before the open!
All previous insights as to direction are invalidated :)
I just looked back and it is now a .6 cent spread after the close to the ask side (does that mean an upswing + news tomorrow?) Go IPIX!
Back to back .3 cent spreads right at the close... yesterday's was the bid being lowered down (stock goes down today). Today's is the ask being lifted up (stock goes up tomorrow?) Let's watch and see!
And the pattern continues...
Another .3 cent spread posted right at the close. After a brisk day of trading it usually has of late brought on early take down attempts the following morning. Lets see what happens at tomorrow's opening and if the pattern continues.
More U.S. Gov’t Spending Fraud and Manipulation of American Tax Dollars.
Fresh outrage as well-connected firms nab US loans!
https://www.msn.com/en-us/news/politics/fresh-outrage-as-well-connected-firms-nab-us-loans/ar-BB16rzP5
Brazil’s President Bolsonaro tests positive for coronavirus!
https://www.msn.com/en-us/news/world/brazils-bolsonaro-tests-positive-for-coronavirus/ar-BB16rzEv?li=BBnb7Kz
I guess the sky's the limit!
Other News:
Novavax skyrockets 41% after US government grants $1.6 billion for coronavirus vaccine creation.
https://www.msn.com/en-us/money/companies/novavax-skyrockets-41percent-after-us-government-grants-dollar16-billion-for-coronavirus-vaccine-creation/ar-BB16rgNd?li=BBnb7Kz
“The grant is the largest yet to be paid out through "Operation Warp Speed," the Trump administration's plan to rapidly develop and deliver a coronavirus vaccine. Novavax aims to use some of the funding for a Phase 3 trial beginning in the fall. The award will also aid the firm in delivering 100 million doses by the end of the year.
CYDY per share today closes up as much as the total value of 1 IPIX share...
Disbelief hovering amongst just the thought of it!
THXS too!
What other gap?
My take is that Brilacidin will be expedited into a phase 3 studies using existing and newly recent admitted hospital patients who have tested positive for Covid-19. It’s documented confirmed low-to-none toxicity data from previous trials demands it. The WhiteHouse administration’s big-wigs have seen the lab data on Brilacidin and are convinced it’s the go to solution for the frontline battle developing rapidly in the onset of a new and never before seen surge of Covid cases and spreads!
I’m sure Leo’s tight-lips on more informative news lately are being induced with the help of laboratory personnel and the government’s health management teams.
Leo’s out there somewhere lining up the development and delivery of gads of Brilacidin product for the upcoming phase 3 trial and beyond!
Go IPIX!!!
No pumping needed... Brilacidin's day is about to break wide open!
Brilacidin is that news! Front and center stage this coming week for sure. Ready yourselves! Glow Bright Brilacidin!!!
Nasdaq's $1.2 trln biotech index draws Europe's COVID drug hunters
https://www.reuters.com/article/health-coronavirus-nasdaq-biotech-idUSL8N2E64SH
Spain’s Pharma Mar is looking at listing on New York’s Nasdaq market, joining a flurry of biotech companies aiming to tap investors’ voracious appetite for the sector as it tests one of its therapies to treat COVID-19.
“Rather than listing directly, Pharma Mar is considering buying a rival in the United States, which could then provide a way to join the Nasdaq.”
“The company could use revenues of as much as $1 billion”
“We could buy an anti-tumor drug maker in the U.S. or a biotech in the U.S.”
Possible suiter for a partnership as well I would think… Eh Leo? How bout' given them a call!
Dang It... I hope we don't have to bow to those blood suckers!
In America... He who pads the lined pockets of politicians with the largest stacks with U.S. green-back currency gets the nod!
As close to today as possible!
What's the lag on the grant?
I'm a believer... I'm a believer... Believing all the time... My' My' My'
Yes, I'm a believer... I'm a believer... Brilacidin in blue skies!
(Tune from the O'Kaysons 1960s "I'm a girl watcher")
Exclusive: You heard it right here on the IPIX board. Cometh on Election Day 11/03/2020 COVID-19 just vaporizes away into fresh air! Didn't Donald Trump tout something like that back early in Feb. or Mar. of this year too? Just different dates, Huh? Good Grief... Tooting Charlie Brown, you make me lmao!
Has Dr. Zelenko Successfully Treated 669 Coronavirus Patients?
A blog post asserting that people responded well to an experimental COVID-19 treatment is in no way an evidence-based contribution to science.
Dr. Vladimir Zelenko's 669 COVID-19 patients that were treated with a combination of hydroxychloroquine, azithromycin, and zinc have seen zero hospitalizations, complications, or deaths.
As has been noted elsewhere, combining hydroxychloroquine and azithromycin can cause serious problems for people with certain heart conditions. Though zinc appears to be an important factor in several immune functions, a potential mechanism for how it might work against viral infections is not well-understood.
In an interview with Forward, Zelenko “acknowledged that his regimen was new and untested, and that it was too soon to assess its long-term effectiveness.” He instead argued that “the risks of waiting to verify its efficacy” were greater. This is an assertion with which public health officials largely disagree.
Regardless, making an assertion in a blog post or in a YouTube interview that neither describes the study design nor provides the actual data used to reach a conclusion about efficacy cannot, in any way, be critically evaluated. As such, this claim is rated “Unproven.”
Leo's almost as transparent as glass. If he has releasable positive news, he would certainly divulge it in haste! IMO
Breakthrough Drug for Covid-19 could be Risky in Mild Patients!
https://www.msn.com/en-us/health/health-news/breakthrough-drug-for-covid-19-may-be-risky-for-mild-cases/ar-BB15W10I?li=BBnb7Kz
Scientists in Britain announced a major breakthrough in the battle against the coronavirus last week, reporting they had found the first drug to reduce deaths among critically ill Covid-19 patients. The results were first made public in a sparsely detailed news release. Now the full study, neither peer reviewed nor published yet, has been posted online, and it holds a surprise. The drug — a cheap, widely available steroid called dexamethasone — does seem to help patients in dire straits, the data suggest. But it also may be risky for patients with milder illness, and the timing of the treatment is critical. The drug “may harm some patients, and we’re not entirely sure which patients those are,” said Dr. Samuel Brown, an assistant professor of pulmonary and critical care medicine at University of Utah School of Medicine in Salt Lake City, who was not involved in the research. Following the announcement last week, officials at some American hospitals said that they would begin to treat coronavirus patients with dexamethasone, and the World Health Organization called for accelerating production to ensure an adequate supply. U.K. health officials moved to limit exports of the steroid.
The drug was tested in a clinical trial that included some 6,425 patients in Britain. One-third were randomly assigned to receive the drug, while the others received the usual care. Patients in the first group received a very low dose of the drug, given daily for up to 10 days. Dexamethasone was beneficial for those who had been sick for more than a week, reducing deaths by one-third among patients on mechanical ventilators and by one-fifth among patients receiving supplemental oxygen by other means. Patients given the steroid who were not receiving respiratory support, however, actually died at a slightly higher rate than similar patients who were not given the drug, although the difference was not statistically significant. That the drug might have disparate effects at different stages of the disease makes sense, given the biology of the illness, according to Dr. Martin J. Landray, the study’s senior author and a professor of medicine and epidemiology at Oxford University. In the most severely ill patients, the immune system flies into a harmful overdrive mode, triggering a so-called cytokine storm that damages the body, including the lungs.
“It’s almost like a disease with two phases,” Dr. Landray said in an interview. “A phase where the virus dominates, and the immunological phase, where the damage the immune system causes is dominant. In the early phase of the illness, the immune system is your friend, it’s fighting the virus, and dampening it is not a good idea.” In the most severely ill patients, the immune system flies into a harmful overdrive mode, triggering a so-called cytokine storm that damages the body, including the lungs. “It’s almost like a disease with two phases,” Dr. Landray said in an interview. “A phase where the virus dominates, and the immunological phase, where the damage the immune system causes is dominant.” Doctors have worried about using steroids such as dexamethasone to fight Covid-19, because steroids are anti-inflammatory drugs that dampen the body’s protective immune response. And in mildly ill patients, that may do more harm than good. “In the early phase of the illness, the immune system is your friend,” Dr. Landray said. “It’s fighting the virus, and dampening it is not a good idea.”
“If a reasonable fraction of patients are recovering in a way that’s satisfactory and welcome, what you have is a gigantic victory,” said Dr. Jeremy Faust, an emergency room physician at Brigham and Women’s Hospital in Boston. Generally, however, patients who have spent a long time on ventilators “have a rough road ahead,” he added, even if dexamethasone improves their odds of survival.
Back at you GL!
Well I'm good with the day!
This morning it became available to lasso a herd of 5000 @ .34356.
Caught'em on the run...
All snarled up @ the upper thirty's, as if someone sprayed sticky foam on the trading table
I'll take a gander and say that we get ether a .44 or .45 cent close today!
It looks like a fairly positive prediction from my twisted perspective...
Wonder which BP sent in the agitator?